Orthofix Medical (NASDAQ:OFIX – Get Rating) will be posting its quarterly earnings results before the market opens on Friday, May 6th. Analysts expect Orthofix Medical to post earnings of $0.18 per share for the quarter. Orthofix Medical has set its FY 2022 guidance at $0.580-$0.730 EPS.
Orthofix Medical (NASDAQ:OFIX – Get Rating) last announced its earnings results on Friday, February 25th. The medical device company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.14. The company had revenue of $125.06 million during the quarter, compared to analysts’ expectations of $124.90 million. Orthofix Medical had a negative net margin of 8.26% and a positive return on equity of 4.84%. During the same quarter in the previous year, the business posted $0.44 earnings per share. On average, analysts expect Orthofix Medical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of OFIX opened at $30.94 on Friday. The company has a 50-day moving average of $32.75 and a two-hundred day moving average of $32.52. The company has a current ratio of 2.55, a quick ratio of 1.76 and a debt-to-equity ratio of 0.06. The stock has a market cap of $614.25 million, a P/E ratio of -15.94 and a beta of 0.99. Orthofix Medical has a 12-month low of $28.65 and a 12-month high of $45.96.
Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its holdings in Orthofix Medical by 129,400.0% in the second quarter. Royal Bank of Canada now owns 1,295 shares of the medical device company’s stock valued at $52,000 after acquiring an additional 1,294 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Orthofix Medical in the third quarter valued at $240,000. Credit Suisse AG boosted its holdings in Orthofix Medical by 6.1% in the fourth quarter. Credit Suisse AG now owns 14,453 shares of the medical device company’s stock valued at $450,000 after acquiring an additional 828 shares during the last quarter. Citigroup Inc. boosted its holdings in Orthofix Medical by 35.0% in the fourth quarter. Citigroup Inc. now owns 18,060 shares of the medical device company’s stock valued at $561,000 after acquiring an additional 4,686 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its stake in shares of Orthofix Medical by 132.5% during the third quarter. BNP Paribas Arbitrage SA now owns 20,469 shares of the medical device company’s stock worth $780,000 after purchasing an additional 11,667 shares in the last quarter. Hedge funds and other institutional investors own 97.54% of the company’s stock.
About Orthofix Medical (Get Rating)
Orthofix Medical Inc operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures.
- Get a free copy of the StockNews.com research report on Orthofix Medical (OFIX)
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
- Iridium Communications Stock is Ready to Return to Orbit
- There’s An Institutional Floor In Keurig Dr. Pepper
Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.